ArticleFrontiers in surgery2026
Outcomes of malignant orbital tumors: a 22-year Norwegian single-center series.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate outcome data for patients with malignant orbital tumors treated at Haukeland University Hospital over a 22 year period and compare them with existing literature. Methods: Patients were identified by searching for relevant codes in the Hospital's database. Medical records from patients with malignant orbital tumors treated from 1999 to 2020 were retrieved. Clinical features, management, and outcome was recorded. Incidence was estimated from yearly population data provided by Statistics Norway. Results: We included 76 patients, 41 (54%) females and 35 (46%) males corresponding to a yearly incidence in Western Norway of 0.30 per 100 000 inhabitants. Median age at time of diagnosis was 64 years (3-97 years). Secondary invading tumors were most frequently seen (46%), followed by lymphoproliferative (24%), metastatic (16%) and primary orbital tumors (14%). Biopsy and histopathologic confirmation were obtained in 73 out of 76 patients (96%). Of 40 different histological subgroups, squamous cell carcinoma from paranasal sinuses was the most common (16%). A total of 42 patients (55%) had their tumor surgically removed, of which 23 patients (55%) underwent exenteration. Local radiotherapy was administrated to 55 (72%) patients and 29 (38%) patients received chemotherapy. One or more local/regional relapses or distant metastases were seen in 32 (42%) patients. Overall disease specific 5-year survival was 59%, with significant differences between subgroups; lymphoproliferative diseases 82%, primary orbital tumors 80%, secondary invading tumors 46%, and orbital metastases 39%. Conclusion: The spectrum of malignant orbital tumors, treatment modalities, and survival rates aligned closely with international literature. While our findings demonstrate that high-quality care is feasible at a low-volume center, further studies on the volume-outcome relationship in orbital oncology is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.